Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of GSK4381562 alone and with anticancer agents in advanced solid tumors
jRCT2031220403Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of GSK4381562 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), breast cancer and 6 more (2 arms), sponsored by GSK. Primary endpoints: Number of participants with dose-limiting toxicities and Number of participants with adverse events and serious adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
GSK4381562
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)breast cancerclear cell renal cell carcinoma (ccRCC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2031220403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220403.